Ipamorelin 5mg
Ipamorelin 5mg
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue by mimicking ghrelin at the GH secretagogue receptor. Its key advantage is high specificity for GH release without triggering ACTH or cortisol elevation, making it
|
Vial Size
|
Dose Range
|
Schedule
|
Primary Goal
|
|---|---|---|---|
| 10 mg vial | 100 to 300 mcg daily with gradual titration; 200 mcg is a common middle-of-the-road dose. | Daily subcutaneous injections for 8 to 12 weeks (extend to 16 weeks if desired), followed by a 2 to 4 week pause to resensitize receptors. | Stimulate endogenous growth hormone release to support anabolic processes related to muscle growth, fat metabolism, and tissue repair. |
Reconstitution Summary
Storage Summary
Ipamorelin 5mg
Reconstitution Steps
- Draw 1 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved (do not shake vigorously).
- Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.
How It Works
Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2 to 3 hours. This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms, though cycling is recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors.
Benefits & Side Effects
- Supports increases in lean body mass and improvements in recovery through GH-mediated anabolic
processes. - Enhances fat metabolism and supports favorable body composition changes over time.
- High selectivity for GH release with minimal impact on other hormones (ACTH, cortisol, prolactin).
- May support improved gastric motility and digestive function.
- Generally well tolerated with a low incidence of side effects at typical doses.
- Occasional mild injection-site reactions (redness, swelling) may occur; very rare reports of water
retention or increased hunger.
References & Scientific Literature
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue (European Journal of Endocrinology, 1998).
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharmaceutical Research, 1999).
- Three-week chronic in vivo ipamorelin treatment: no desensitization of GH release (European Journal of Anatomy, 2002).
- Ipamorelin for postoperative ileus in bowel resection patients (Int J Colorectal Disease, 2014).